From GlobeNewswire: 2025-06-03 13:31:00

The global Epigenetics market is projected to grow from $4.8 billion in 2024 to $8.5 billion by 2029, with a CAGR of 11.8%. The report covers therapeutic classes, study methods, clinical indications, and drug classes, with insights on industry growth drivers, trends, and emerging technologies impacting the market.

Key market growth factors include rising cancer rates, technological advances, increased research funding, precision medicine, and interest in liquid biopsy for disease detection and monitoring.

Leading companies in the epigenetics market include ACTIVE MOTIF INC., BIO-RAD LABORATORIES INC., and THERMO FISHER SCIENTIFIC INC. Startups like Helio Genomics and Biomea Fusion are innovating in early cancer detection and the development of small molecules for metabolic diseases and cancers.

The global epigenetics market is expected to reach $8.5 billion by 2029, with the In Vitro Diagnostics (IVD) segment projected to dominate. The fastest-growing market segment is also the IVD segment, with a CAGR of 11.8% from 2024 to 2029.

To navigate uncertainty with confidence, BCC Research offers 30% off their reports to provide comprehensive market insights for informed decision-making. Reports cover liquid biopsy research tools, diagnostics, DNA sequencing, and more in the evolving landscape of biomedical research and innovation.



Read more at GlobeNewswire: Epigenetics Market Anticipated to Achieve 11.8% CAGR